Stockreport

Zenas BioPharma Funding Supports Obexelimab Plans After Pullback In Shares [Yahoo! Finance]

Zenas BioPharma, Inc.  (ZBIO) 
PDF Zenas BioPharma secured a $250 million non-dilutive loan agreement to support commercialization and development of obexelimab. The financing follows positive Phase 3 [Read more]